The win ratio for evaluating edoxaban vs dalteparin for cancer-associated venous thromboembolism: an analysis of the randomized Hokusai Venous Thromboembolism Cancer trial
We observed no significant difference between edoxaban and dalteparin for the treatment of cancer-associated VTE when using the win ratio approach with a hierarchy of 10 prioritized outcomes.
Authors
- Björn Redfors (ORCID: https://orcid.org/0000-0002-4155-4451)
- Luuk J.J. Scheres (ORCID: https://orcid.org/0000-0001-5282-5520)
- Marcello Di Nisio (ORCID: https://orcid.org/0000-0001-5930-7304)
- Kristen M. Sanfilippo (ORCID: https://orcid.org/0000-0002-0433-7845)
- Peter Verhamme (ORCID: https://orcid.org/0000-0001-8698-2858)
- William F. McIntyre (ORCID: https://orcid.org/0000-0001-6082-7542)
- Patrick M. Bossuyt (ORCID: https://orcid.org/0000-0003-4427-0128)
- Nick van Es (ORCID: https://orcid.org/0000-0001-5256-6346)
- Renato D. Lópes (ORCID: https://orcid.org/0000-0003-2999-4961)
- Deborah M. Siegal (ORCID: https://orcid.org/0000-0003-3806-3245)
- Jeffrey Ian Weitz (ORCID: https://orcid.org/0000-0002-1092-7550)
- Marc Carrier
- Annelise Segers
- Michael Grosso
- Harry Büller
Institutions
- Radboud University Nijmegen (NL)
- University of Ottawa (CA)
- Cornell University (US)
- Leiden University Medical Center (NL)
- Ottawa Hospital (CA)
- Sahlgrenska University Hospital (SE)
- Population Health Research Institute (CA)
- Radboud University Medical Center (NL)
- University of Chieti-Pescara (IT)
- St. Louis VA Medical Center (US)
- Amsterdam Neuroscience (NL)
- Health Action International (NL)
- Duke Medical Center (US)
- Amsterdam University Medical Centers (NL)
- Thrombosis and Atherosclerosis Research Institute (CA)
- Daiichi Sankyo (United States) (US)
- Saint Louis University (US)
- University of Amsterdam (NL)
- KU Leuven (BE)
Publication Details
- Journal
- Journal of Thrombosis and Haemostasis
- Published
- 2025-12-19
- DOI
- https://doi.org/10.1016/j.jtha.2025.11.024
- Primary Topic
- Venous Thromboembolism Diagnosis and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00